RainDance Technologies and Ambry Genetics have launched ADMESeq, a targeted sequencing panel that will sequence 242 genes involved with drug absorption, distribution, metabolism, and excretion.
Ambry Genetics will be the first authorized service provider for a new high-throughput target enrichment system being developed by RainDance Technologies, the companies announced last week.
By Justin Petrone
Growing demand for arrays designed to detect tumor copy-number changes is enticing more chip manufacturers to offer tools tailor-made for cancer research.
Ambry's StemArray is manufactured by Roche NimbleGen and enables researchers studying stem cells to detect genomic abnormalities that would ordinarily be missed by low-resolution karyotyping.
Ambry Genetics is now able to offer all Roche NimbleGen applications, the first of Roche NimbleGen's growing list of service providers to achieve such certification.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
